New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 912-920

  Marciani, Dante J ^a  

^a Qantu Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; GAMMA INTERFERON; GLYCAN; GLYCOSIDE; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; PROTEIN ANTIBODY; TRITERPENIC GLYCOSIDE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ALZHEIMER DISEASE; CD8+ T LYMPHOCYTE; DEGENERATIVE DISEASE; DETERIORATION; DRUG EFFECT; HELMINTH; HUMAN; IMMUNE RESPONSE; IMMUNOSENESCENCE; IMMUNOSTIMULATION; INFLAMMATION; LYMPHOCYTOPOIESIS; NEURODEGENERATIVE PROTEINOPATHY; NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CONFORMATION; PROTEIN SECRETION; REVIEW; SENESCENCE; TH1 CELL; TH2 CELL; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; NEURODEGENERATIVE DISEASES; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ANIMALS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEURODEGENERATIVE DISEASES; TH2 CELLS;

EID: 84903757911     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.02.015     Document Type: Review

References (70)

1. A.L. Southwell, and P.H. Patterson Antibody therapy in neurodegenerative disease Rev. Neurosci. 21 2010 273 287
2. S.S. Sisodia Alzheimer's disease: perspectives for the new millennium J. Clin. Invest. 104 1999 1169 1170 (Pubitemid 29536286)
3. H.J. Fu et al. Amyloid-beta immunotherapy for Alzheimer's disease CNS Neurol. Disord. Drug Targets 9 2010 197 206
4. L. Crews, and E. Masliah Molecular mechanisms of neurodegeneration in Alzheimer's disease Hum. Mol. Genet. 19 2010 12 20
5. S. Gandy The role of amyloid beta accumulation in common forms of Alzheimer's disease J. Clin. Invest. 115 2005 1121 1129 (Pubitemid 40629026)
6. U. Neniskyte et al. Neural death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia J. Biol. Chem. 286 2011 39904 39913
7. D.J. Selkoe Toward a comprehensive theory of Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid-beta protein Ann. N. Y. Acad. Sci. 924 2000 17 25 (Pubitemid 32050177)
8. J. Naslund et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging Proc. Natl. Acad. Sci. U. S. A. 91 1994 8378 8382 (Pubitemid 24273667)
9. S.A. Gravina et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42 (43) J. Biol. Chem. 1270 1995 7013 7016
10. S.G. Younkin Evidence that A beta 42 is the real culprit in Alzheimer's disease Ann. Neurol. 37 1995 287 288
11. M. Kolarova et al. Structure and pathology of tau protein in Alzheimer's disease Int. J. Alzheimers Dis. 2012 2012 732526
12. H.C. Huang, and Z.F. Jiang Accumulated amyloid-beta peptide and hyper-phosphorylated tau protein: relationship and links in Alzheimer's disease J. Alzheimers Dis. 16 2009 15 27
13. K. Ubhi, and E. Masliah Recent advances in the development of immuno-therapies for tauopathies Exp. Neurol. 230 2011 157 161
14. J. Avila Intracellular and extracellular tau Front. Neurosci. 4 2010 49
15. J. Ming et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration Proc. Natl. Acad. Sci. U. S. A. 108 2011 5819 5824
16. R.A. Quintanilla et al. Truncated tau and Aβ cooperatively impair mitochondria in primary neurons Neurobiol. Aging 33 2012 e25 e35
17. D. Schenk et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177 (Pubitemid 29327547)
18. D. Schenk et al. Current progress in beta-amyloid immunotherapy Curr. Opin. Immunol. 16 2004 599 606 (Pubitemid 39165888)
19. D.M. Wilcock et al. Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses ASN Neuro. 3 2011 249 258
20. D.S. Gelinas et al. Immunotherapy for Alheimer's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 14657 14662
21. C.R. Kensil et al. QS-21 and QS-7: purified saponin adjuvants Dev. Biol. Stand. 92 1998 41 47
22. J. Naslund et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 83 2000 1571 1577 (Pubitemid 30161512)
23. D.J. Marciani Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity Drug Discov. Today 8 2003 934 943 (Pubitemid 37230013)
24. M. Britschgi et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 106 2009 12145 12150
25. J. Kofler et al. Preventive immunization of aged and juvenile non-human primates to beta-amyloid J. Neuroinflammation 9 2012 84
26. F. Bard et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc. Natl. Acad. Sci. U. S. A. 10 2003 2023 2028 (Pubitemid 36254567)
27. Y. Du et al. Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity Brain 126 2003 1935 1939 (Pubitemid 37059433)
28. T. Wisniewski, and U. Konietzko Amyloid-β immunisation for Alzheimer's disease Lancet Neurol. 7 2008 805 811
29. D.M. Wilcock, and C.A. Colton Anti-Aβ immunotherapy in Alzheimer's disease; relevance of transgenic mice studies to clinical trials J. Alzheimers Dis. 15 2008 555 569
30. J. Ongradi, and D. Kövesdi Factors that may impact on immunosenescence: an appraisal Immun. Ageing 7 2010 7
31. R. Aspinall et al. Challenges for vaccination in the elderly Immun. Ageing 4 2007 9
32. T.P. Plackett et al. Aging and innate immune cells J. Leukoc. Biol. 76 2004 291 299 (Pubitemid 39006941)
33. T. Su-Yi, and M.L. Dustin T-cell activation: a multidimensional signaling network Curr. Opin. Cell Biol. 14 2002 575 580 (Pubitemid 35247740)
34. D. Frasca et al. Age effects on B cells and humoral immunity in humans Ageing Res. Rev. 10 2011 330 335
35. X.-G. Luo et al. Microglia in the aging brain: relevance to neurodegeneration Mol. Neurodegener. 5 2010 12
36. S. Akira et al. Pathogen recognition and innate immunity Cell 124 2006 783 801 (Pubitemid 43261452)
37. Y. Cai et al. Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice J. Oral. Sci. 55 2013 107 114
38. E. De Gregorio et al. Alum adjuvanticity: unraveling a century old mystery Eur. J. Immunol. 38 2008 2068 2071
39. P. Marrack et al. Towards an understanding of the adjuvant action of aluminium Nat. Rev. Immunol. 9 2009 287 293
40. A.A. Asuni et al. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages Eur. J. Neurosci. 24 2006 2530 2542 (Pubitemid 44726765)
41. J.P. Hewitson et al. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity Mol. Biochem. Parasitol. 167 2009 1 11
42. P.G. Thomas, and D.A. Harn Immune biasing by helminth glycans Cell Microbiol. 6 2004 13 22 (Pubitemid 38111585)
43. S. Tundup et al. Polarization of host immune responses by helminth-expressed glycans Ann. N. Y. Acad. Sci. 1253 2012 E1 E13
44. M. Okano et al. Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response J. Immunol. 167 2001 442 450 (Pubitemid 32567810)
45. S.-C. Hsu et al. Antigen coupled with Lewis-x trisaccharides elicits potent immune responses in mice J. Allergy Clin. Immunol. 119 2007 1522 1528 (Pubitemid 46855835)
46. I. Van Die, and R.D. Cummings Glycan gimmickry by parasitic helminths: a strategy for modulating the host immune response? Glycobiology 20 2010 2 12
47. S. Steinfelder et al. The major component in schistosome eggs responsible for conditioning dendritic cells for Th2 polarization is T2 ribonuclease (omega-1) J. Exp. Med. 206 2009 1681 1690
48. B. Everts et al. Schistosome-derived omega-1 drives Th2 polarization by suppressing protein synthesis following internalization by the mannose receptor J. Exp. Med. 209 2012 1753 1767
49. J.B. Press et al. Structure/function relationships of immunostimulating saponins Stud. Nat. Prod. Chem. 24 2000 131 174
50. S. Soltysik et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function Vaccine 13 1995 1403 1410
51. C.R. Kensil et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex J. Immunol. 146 1991 431 437
52. A. Sjölander et al. ISCOMs: an adjuvant with multiple functions J. Leukoc. Biol. 64 1998 713 723 (Pubitemid 28555383)
53. D.J. Marciani et al. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins Int. Immunopharmacol. 1 2001 813 818 (Pubitemid 32206543)
54. D.J. Marciani et al. Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 subunit vaccine Int. Immunopharmacol. 2 2002 1703 1711 (Pubitemid 35284608)
55. Beltz, G. et al. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient. WO 1999010008 A1, March 4, 1999
56. A. Ghochikyan et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch Vaccine 24 2006 2275 2282 (Pubitemid 43290409)
57. H. Davtyan et al. Immunogenicity, efficacy, safety and mechanism of action of epitope vaccine (LuAF20513) for Alzheimer's disease: prelude to a clinical trial J. Neurosci. 3 2013 4923 4934
58. J. Delrieu et al. 'Clinical trials in Alzheimer's disease': immunotherapy approaches J. Neurochem. 120 Suppl. 1 2012 186 193
59. S.R. Chavali et al. Immunopotentiation by orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally against rabies Clin. Exp. Immunol. 74 1988 339 343 (Pubitemid 19039719)
60. G. Shi et al. Differential involvement of Th1 and Th17 in pathogenic autoimmune processes triggered by different TLR ligands J. Immunol. 191 2013 1415 1423
61. J. Rhodes et al. Therapeutic potentiation of the immune system by co-stimulatory Schiff-base forming drugs Nature 377 1995 71 75
62. D.J. Marciani et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity Vaccine 18 2000 3145 3151
63. C.M. Snapper, and W.E. Paul Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production Science 236 1987 944 947 (Pubitemid 17107942)
64. N.B. Chauhan, and G.J. Siegel Efficacy of anti-Beta antibodies isotypes used for intracerebroventricular immunization in TgCRND8 Neurosci. Lett. 375 2005 143 147 (Pubitemid 40202940)
65. N. Melzer et al. CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability FASEB J. 23 2009 3659 3673
66. M.T. Siirin et al. Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters Am. J. Trop. Med. Hyg. 79 2008 955 962
67. A.M. Daines et al. Mannosylated saponins based on oleanoloic and glycyrrhizic acids. Towards synthetic colloidal antigen delivery systems Bioorg. Med. Chem. 17 2009 5207 5218
68. T. Tabira Immunization therapy for Alzheimer's disease: a comprehensive review of active immunization strategies Tohoku J. Exp. Med. 220 2010 95 106
69. C. Wiessner et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects J. Neurosci. 31 2009 9323 9331
70. B. Winblad et al. Safety, tolerability and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomized, double-blind, placebo-controlled, first-in-human study Lancet Neurol. 11 2012 597 604